Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-29T01:40:54.863Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of Higher-Dose Intradermal Hepatitis B Vaccination to Standard Intramuscular Vaccination of Healthcare Workers

Published online by Cambridge University Press:  02 January 2015

Elizabeth A. Henderson ,
Thomas J. Louie ,
Karam Ramotar ,
Donna Ledgerwood ,
Karen Myrthu Hope  and
Agnes Kennedy
Elizabeth A. Henderson*
Affiliation:
Calgary Regional Health Authority, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada Departments of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
Thomas J. Louie
Affiliation:
Calgary Regional Health Authority, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada Department of Microbiology and Infectious Diseases, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
Karam Ramotar
Affiliation:
Calgary Regional Health Authority, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada Department of Microbiology and Infectious Diseases, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
Donna Ledgerwood
Affiliation:
Calgary Regional Health Authority, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
Karen Myrthu Hope
Affiliation:
Calgary Regional Health Authority, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
Agnes Kennedy
Affiliation:
Calgary Regional Health Authority, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
*
Infection Prevention and Control, Peter Lougheed Center of the Calgary General Hospital, 3500—26 Ave NE, Calgary, Alberta T1Y6J4, Canada
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To compare the immunogenicity of hepatitis B vaccine administered via intradermal (ID) versus intramuscular (IM) route.

Methods:

Subjects chose either to specify the route of immunization or to undergo random allocation to vaccination by the ID (0.15 mL) or the IM (1.0 mL) route. Yeast-derived recombinant hepatitis B vaccine was given at 0, 30, and 180 days. Hepatitis B surface antibody (HBsAb) and hepatitis B core antibody (HBcAb) were measured by microparticle enzyme immunoassay.

Results:

763 subjects were enrolled. Baseline screening identified 65 subjects (8%) who were positive for HBsAb or HBcAb. Vaccination was completed by 590 (85%) of 698 enrollees (370 ID, 220 IM). Seroconversion rates (geometric mean titers [GMT]>0 IU/mL HBsAb) for those vaccinated ID were 99% and 96% for screening at 9 months and 1 year post-vaccination, respectively; subjects vaccinated intramuscularly had similar rates of 95% and 96%. Seropositivity rates (GMT ≥ 10 IU/mL HBsAb) showed a similar pattern, with 95%, 92%, and 73% at 9 months and 1 and 2 years, respectively, for those vaccinated ID, and 94%, 93%, and 81% for those having IM vaccination. GMT for HBsAb was significantly higher for individuals vaccinated IM than for those vaccinated ID (P<.0001). The GMT ratio for the IM and ID routes decreased over time, being 9.3 at 9 months, 7.8 at 1 year, and 5.9 at 2 years. An unanticipated side effect of intradermal vaccination was skin discoloration at injection sites, which persisted for at least 2 years postvaccination. Two thirds (112/166) of respondents reported that they would have selected the ID route despite the discoloration.

Conclusions:

Higher-dose ID vaccination (3 vs 1 μg per injection) uses one sixth of the dose required for standard IM vaccination. It is a cost-effective way to vaccinate populations against hepatitis B virus, but the long-term efficacy of the ID route must still be investigated.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 21 , Issue 4 , April 2000 , pp. 264 - 269
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bryan, J, Iqbal, M, Sjogren, M, et al. Low-dose intradermal recombinant hepatitis B vaccine. ICAAC. Houston, TX; September 1989;133. Abstract 196.Google Scholar
2.Lancaster, D, Elam, S, Kaiser, AB. Immunogenicity of the intradermal route of hepatitis B vaccination with the use of recombinant hepatitis B vaccine. Am J Infect Control 1989;17:126–129.CrossRefGoogle ScholarPubMed
3.Bryan, JP, Sjogren, M, Iqbal, M, Khattak, AR, Nabi, S, Ahmed, A, et al. Comparative trial of low-dose, intradermal, recombinant- and plasma-based hepatitis B vaccines. J Infect Dis 1990;162:789–793.CrossRefGoogle Scholar
4.Heijtink, RA, Breukers, AA, den Hartigh, G, Schepman, RW, Schmitz, I, Schalm, SW, et al. Low-dose intradermal vaccination against hepatitis B in mentally retarded patients. Vaccine 1988;6:59–61.CrossRefGoogle ScholarPubMed
5.McMaster, KR III, Roper, JK, Carter, JB. Intradermal hepatitis B vaccination in a 300-bed primary care hospital: experience with a recombinant vaccine in a four-dose schedule. Am J Infect Control 1993;21:283–288.CrossRefGoogle Scholar
6.Parish, DC, Muecke, HW, Joiner, TA, Pope, WT, Haider, SC. Immunogenicity of low-dose intradermal recombinant DNA hepatitis B vaccine. Southern Medical Journal 1991;84:426–430.CrossRefGoogle ScholarPubMed
7.Wistrom, J, Settergren, B, Gustafsson, A, Juto, P, Norrby, RS. Intradermal versus intramuscular hepatitis B vaccination. JAMA 1990;264:181–182.CrossRefGoogle Scholar
8.Redfield, RR, Innis, BL, Scott, RM, Cannon, HG, Bancroft, WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: a cost strategy. JAMA 1985;254:3203–3206.CrossRefGoogle Scholar
9.Prasetya, E, Linggadjaja, W, Syambali, R, Kusumo, S, Dharmesetyawan, DF, Rahardja, U. Intradermal vaccination against hepatitis B in Immanuel Hospital personnel—a preliminary report. Ann Academic Medicine 1986;15:153–157.Google ScholarPubMed
10.Halsey, NA, Reppert, EJ, Margolis, HS, Francis, DP, Fields, HA. Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine 1986;4:228–232.CrossRefGoogle Scholar
11.Wahl, M, Hermodsson, S. Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: side effects and antibody response. Scandinavian Journal of Infectious Diseases 1987;19:617–621.CrossRefGoogle ScholarPubMed
12.Gonzalez, ML, Usandizaga, M, Alomar, P, Salva, F, Martin, F, Erroz, MJ, et al. Intradermal and intramuscular route for vaccination against hepatitis B. Vaccine 1990;8:402–404.CrossRefGoogle ScholarPubMed
13.Bryan, JP, Sjogren, MH, Perine, PL, Legters, LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 1991;14:697–707.CrossRefGoogle Scholar
14.Hadler, SC, Francis, DP, Maynard, JE, Thompson, SE, Judson, FN, Echenberg, DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315: 209–214.CrossRefGoogle ScholarPubMed
15.Barnes, GP, Hanacik, LJ. Hepatitis B Vaccine: persistence of antibody following immunization. Infect Control Hosp Epidemiol 1988;9:147–150.CrossRefGoogle Scholar
16.McKinney, WP, Horowitz, M, Battiola, R, Russler, S. Duration of response to intramuscular versus low-dose intradermal hepatitis B booster vaccination. ICAAC. Houston, TX; September 1989;17:131. Abstract 181.Google Scholar
17.West, DJ. Clinical experience with hepatitis B vaccine. Am J Infect Control 1989;17:172–180.CrossRefGoogle Scholar
18.Centers for Disease Control. Update on hepatitis B prevention. MMWR 1987;36:353–366.Google Scholar
19.Szmuness, W, Stevens, CE, Harley, EJ. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982;307:1481–1486.CrossRefGoogle ScholarPubMed
20.Szmuness, W, Stevens, CE, Zang, EA, Harley, EJ, Kellner, A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptovax B): a final report. Hepatology 1981;1:377–385.CrossRefGoogle Scholar
21.Krugman, S, Davidson, M. Hepatitis B vaccine: prospects for duration of immunity. Yale Journal of Biological Medicine 1987;60:333–338.Google ScholarPubMed